Objectives of Study:
|
Allergic rhinitis (AR), also known as allergic rhinitis, is a common inflammatory disease of nasal mucosa triggered by allergens in the environment and mediated by IgE. Its clinical manifestations are itching, sneezing, runny nose and nasal congestion, which induce asthma. AR is a refractory disease in otolaryngology. Although ar does not directly threaten the lives of patients, nasal and ocular symptoms and complications seriously affect the quality of life and physical and mental health of patients, and become a global health problem.
According to the literature, there are more than 500 million ar patients worldwide. The prevalence of allergic rhinitis in Beijing was 9.7%. The treatment principles of AR in modern medicine include environmental control, drug therapy, immunotherapy and health education. Drug therapy and immunotherapy are the main treatment methods, the purpose of treatment is to control the symptoms of patients and improve the quality of life, but it can not be completely cured, and may lead to a variety of adverse reactions. Therefore, many ar patients in China seek the treatment of traditional Chinese medicine. Some randomized controlled trials carried out in China also show that Chinese herbal medicine is effective in improving the symptoms of patients with allergic rhinitis, and has good safety. At present, there is still a lack of high-quality, large sample and long-term observation of clinical studies, and the evidence of evidence-based medicine is not sufficient.
The prescription used in this study comes from Professor Wang Qi's effective experience in the treatment of ar - desensitization Zhichou decoction, which is composed of Wumei, cicada slough, Magnolia, Xanthium sibiricum, Astragalus and other traditional Chinese medicine. In recent years, our basic research and clinical case observation studies have preliminarily shown that the formula has anti allergic effect, can improve the symptoms of AR patients and reduce recurrence. Therefore, this study intends to carry out randomized controlled trials to evaluate the efficacy and safety of this prescription in the treatment of AR, and provide high-quality evidence-based medical support for clinical application.
|
Inclusion criteria
|
Inclusion criteria
All the following conditions should be met for the included patients:
(1) Those who met the diagnostic criteria of moderate to severe persistent allergic rhinitis;
(2) According to the international diagnostic criteria (ARIA) of AR:
① Clinical symptoms: two or more symptoms such as sneezing, clear water like runny nose, nasal itching and nasal congestion, lasting or accumulating for more than 1 hour every day;
② Allergen test: at least one allergen SPT and / or serum specific IgE were positive.
(3) The TNSS score should be ≥ 4.
(4) They were 18-65 years old;
(5) Informed consent, signed informed consent form, and volunteers.
|
Exclusion criteria:
|
Exclusion criteria
Those with one of the following conditions will be excluded from this study:
(1) Patients with acute sinusitis or respiratory tract infection in the past two weeks;
(2) Patients with bronchial asthma, moderate or above atopic dermatitis, immune diseases and severe chronic inflammatory diseases;
(3) History of drug allergy;
(4) Those who have received specific immunotherapy in the past two years, and those who have received anti allergic Chinese medicine, systemic hormone therapy or antihistamine therapy in the past two weeks;
(5) Pregnant or lactating patients.
(6) Severe lung, liver, kidney disease or other serious primary disease.
|